Last reviewed · How we verify
cyclophosphamide or azathioprine
Cyclophosphamide and azathioprine are alkylating agents that interfere with DNA replication, thereby inhibiting cancer cell growth.
Cyclophosphamide and azathioprine are alkylating agents that interfere with DNA replication, thereby inhibiting cancer cell growth. Used for Treatment of certain types of leukemia, lymphoma, and other cancers, Prevention of organ transplant rejection.
At a glance
| Generic name | cyclophosphamide or azathioprine |
|---|---|
| Sponsor | Sun Yat-sen University |
| Drug class | Alkylating agent |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
They work by attaching an alkyl group to the DNA of cancer cells, which prevents the cells from replicating. This leads to cell death and ultimately, tumor shrinkage. Both drugs are used in chemotherapy regimens to treat various types of cancer.
Approved indications
- Treatment of certain types of leukemia, lymphoma, and other cancers
- Prevention of organ transplant rejection
Common side effects
- Myelosuppression
- Nausea and vomiting
- Hair loss
- Fatigue
- Infection
Key clinical trials
- Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease (PHASE4)
- Rituximab in Eosinophilic Granulomatosis With Polyangiitis (PHASE3)
- Different Immunosuppressive Treatment in iMN (PHASE3)
- BDB-001 Phase III Trial in ANCA-Associated Vasculitis (PHASE3)
- Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia (PHASE2)
- A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis (PHASE3)
- Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) (PHASE2)
- Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cyclophosphamide or azathioprine CI brief — competitive landscape report
- cyclophosphamide or azathioprine updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI